Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine
| Autor: | J. P. Chiron, L. Bringer, Pierre Coursaget, C. Blondeau, C. Bourdil, E. Jeannée, G. Sarr, S. Guindo, B. Yvonnet, I. Diop-Mar, B. Fritzell |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Viral Hepatitis Vaccines
Hepatitis B virus Hepatitis B vaccine Molecular Sequence Data Recombinant virus medicine.disease_cause Hepatitis B Antigens Medicine Humans Hepatitis B Vaccines Amino Acid Sequence Seroconversion Hepatitis B Antibodies Vaccines Synthetic General Veterinary General Immunology and Microbiology biology business.industry Immunogenicity Vaccination Public Health Environmental and Occupational Health Infant Hepatitis B biology.organism_classification medicine.disease Virology Infectious Diseases Hepadnaviridae Immunology Molecular Medicine business |
| Zdroj: | Vaccine. 10(6) |
| ISSN: | 0264-410X |
| Popis: | Three doses of hepatitis B vaccine were given at 2, 4 and 9 months of age to 220 Senegalese infants living in the Dakar area of Senegal. Half of the infants received 5 micrograms plasma-derived hepatitis B vaccine (Hevac B) and the remainder 20 micrograms mammalian cell-derived recombinant hepatitis B vaccine (GenHevac B). Both vaccines contain S and pre-S2 encoded proteins; however, the recombinant vaccine had a much higher pre-S2 content than the plasma-derived vaccine. Adverse reactions to both vaccines were limited to mild and transient soreness at the injection site. Fever was reported in 14-21% of the infants and was likely to be related to DTP-polio vaccine which was given simultaneously. After the two first doses, seroconversion rates and geometric mean titres of anti-HBs were higher in infants receiving the recombinant vaccine than in infants receiving the plasma-derived vaccine. After completion of vaccination, all infants in both groups had protective levels of anti-HBs antibodies. The recombinant vaccine induced more rapidly antibodies directed against S and pre-S2 epitopes. Anti-pre-S2 antibodies were detected after the first injection of GenHevac B and only after the third injection of Hevac B. From the data, GenHevac B vaccine is expected to be as effective as Hevac B vaccine for controlling hepatitis B infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|